牛牛AI助理已提取核心訊息
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has regained compliance with Nasdaq's minimum bid price requirement. The company, which is based in Washington D.C. and has a subsidiary in Australia, was previously notified by Nasdaq on February 27, 2024, that its common stock did not maintain the required minimum bid price of $1.00 for 30 consecutive business days. However, between August 12, 2024, and August 23, 2024, the company's stock price consistently closed at or above $1.00, satisfying the Nasdaq Listing Rule 5550(a)(2). The closing price on August 23, 2024, was reported at $1.81. Following this achievement, 60 Degrees Pharmaceuticals issued a press release on August 28, 2024, to announce its compliance with the Bid Price Rule. The company, founded in 2010, is known for its FDA-approved malaria prevention drug, ARAKODA® (tafenoquine), and collaborates with research organizations in the U.S., Australia, and Singapore. It has received support from the U.S. Department of Defense and private investors, including Knight Therapeutics Inc.
60 Degrees Pharmaceuticals, Inc., a pharmaceutical company specializing in infectious disease treatments, has regained compliance with Nasdaq's minimum bid price requirement. The company, which is based in Washington D.C. and has a subsidiary in Australia, was previously notified by Nasdaq on February 27, 2024, that its common stock did not maintain the required minimum bid price of $1.00 for 30 consecutive business days. However, between August 12, 2024, and August 23, 2024, the company's stock price consistently closed at or above $1.00, satisfying the Nasdaq Listing Rule 5550(a)(2). The closing price on August 23, 2024, was reported at $1.81. Following this achievement, 60 Degrees Pharmaceuticals issued a press release on August 28, 2024, to announce its compliance with the Bid Price Rule. The company, founded in 2010, is known for its FDA-approved malaria prevention drug, ARAKODA® (tafenoquine), and collaborates with research organizations in the U.S., Australia, and Singapore. It has received support from the U.S. Department of Defense and private investors, including Knight Therapeutics Inc.
60度製藥公司是一家專門從事傳染病治療的藥品公司，已恢復符合納斯達克的最低買盤價格要求。該公司總部位於華盛頓特區，並在澳洲設有子公司。該公司此前於2024年2月27日收到納斯達克的通知，其普通股連續30個業務日未能維持每股至少1.00美元的最低買盤價格要求。然而，在2024年8月12日至2024年8月23日期間，該公司股價連續收盤在或高於1.00美元，滿足納斯達克上市規則5550(a)(2)。2024年8月23日收盤價報告爲1.81美元。在取得這一成就後，60度製藥公司於2024年8月28日發佈新聞稿宣佈其符合買盤價格規則。該公司成立於2010年，以其獲得FDA批准的瘧疾預防藥物ARAKODA®（噻醇）聞名，並與美國、澳洲和新加坡的研究機構合作。它獲得了美國國防部和包括Knight Therapeutics Inc在內的私人投資者的支持。
60度製藥公司是一家專門從事傳染病治療的藥品公司，已恢復符合納斯達克的最低買盤價格要求。該公司總部位於華盛頓特區，並在澳洲設有子公司。該公司此前於2024年2月27日收到納斯達克的通知，其普通股連續30個業務日未能維持每股至少1.00美元的最低買盤價格要求。然而，在2024年8月12日至2024年8月23日期間，該公司股價連續收盤在或高於1.00美元，滿足納斯達克上市規則5550(a)(2)。2024年8月23日收盤價報告爲1.81美元。在取得這一成就後，60度製藥公司於2024年8月28日發佈新聞稿宣佈其符合買盤價格規則。該公司成立於2010年，以其獲得FDA批准的瘧疾預防藥物ARAKODA®（噻醇）聞名，並與美國、澳洲和新加坡的研究機構合作。它獲得了美國國防部和包括Knight Therapeutics Inc在內的私人投資者的支持。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了